Supraventricular tachycardia associated with continuous furosemide infusion

Wilson, Nigel; Adderley, Robert J.; McEniery, Julie

doi:10.1007/bf03007589

Cited by 11 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three cases of supraventricular tachycardia, associated with the use of furosemide infusion following cardiac surgery, were reported by Wilson et al [83]. The supraventricular tachycardia occurred 3 to 7 h after starting an intravenous infusion of furosemide at 1.0 mg/kg/h.…”

Section: Resultsmentioning

confidence: 99%

Clinical Pharmacology of Furosemide in Neonates: A Review

Pacifici

2013

Pharmaceuticals

View full text Add to dashboard Cite

Furosemide is the diuretic most used in newborn infants. It blocks the Na+-K+-2Cl− symporter in the thick ascending limb of the loop of Henle increasing urinary excretion of Na+ and Cl−. This article aimed to review the published data on the clinical pharmacology of furosemide in neonates to provide a critical, comprehensive, authoritative and, updated survey on the metabolism, pharmacokinetics, pharmacodynamics and side-effects of furosemide in neonates. The bibliographic search was performed using PubMed and EMBASE databases as search engines; January 2013 was the cutoff point. Furosemide half-life (t1/2) is 6 to 20-fold longer, clearance (Cl) is 1.2 to 14-fold smaller and volume of distribution (Vd) is 1.3 to 6-fold larger than the adult values. t1/2 shortens and Cl increases as the neonatal maturation proceeds. Continuous intravenous infusion of furosemide yields more controlled diuresis than the intermittent intravenous infusion. Furosemide may be administered by inhalation to infants with chronic lung disease to improve pulmonary mechanics. Furosemide stimulates prostaglandin E2 synthesis, a potent dilator of the patent ductus arteriosus, and the administration of furosemide to any preterm infants should be carefully weighed against the risk of precipitation of a symptomatic patent ductus arteriosus. Infants with low birthweight treated with chronic furosemide are at risk for the development of intra-renal calcifications.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Pharmacology of Furosemide in Neonates: A Review

Pacifici

2013

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Supraventricular tachycardia associated with continuous infusion of high dose furosemide (0.75-1 mg/kg BW ⋅ h), caused by a rapid fluid shift in the intravascular volume produced by furosemide administration and drug-related fever have been reported [9,10].…”

Section: Discussionmentioning

confidence: 99%

Intermittent administration of furosemide versus continuous infusion in the postoperative management of children following open heart surgery

Klinge

Scharf

Hofbeck

et al. 1997

Intensive Care Medicine

View full text Add to dashboard Cite

show abstract

“…27 In that report, the arrhythmias converted to sinus rhythm in all patients upon discontinuation of the infusion and correction of the potassium levels. These arrhythmias may have been triggered by large intercompartmental shifts in fluid (UOP ≥8 mL/kg/h) and electrolytes (serum potassium ≤3.6 mEq/L).…”

Section: Discussionmentioning

confidence: 89%

“…Wilson et al 27 described 3 cases of supraventricular tachycardia (SVT) associated with the use of a continuous furosemide infusion in pediatric patients. The patients were 15 days, 4 months, and 17 months old, and all were initiated on a 1 mg/kg/h furosemide infusion on postoperative day 7 or later.…”

Section: Safety Concernsmentioning

confidence: 99%